 |
135 Diseases |  |
108 Trials |
|
108 Trials |  |
2708 News |  |
| 12345678910111213...4243» |
- | leuprolide acetate for depot suspension / Generic mfg.
Journal: Leuprorelin Suppresses Angiogenesis and Malignant Progression in Endometrial Cancer via Downregulation of the ELAVL1/VEGFA Axis. (Pubmed Central) - Nov 9, 2026
In nude mouse xenograft models, leuprorelin administration suppressed tumor growth and tumor-associated neovascularization, effects that were reversed upon VEGFA overexpression. Leuprorelin impedes EC progression by disrupting ELAVL1-mediated stabilization of VEGFA mRNA, highlighting the ELAVL1/VEGFA axis as a potential therapeutic target for anti-angiogenic therapeutic intervention.
- | leuprolide acetate for depot suspension / Generic mfg.
Preclinical, Journal: Leuprolide acetate improves ovarian indices but does not restore uterine morphometry in obese Zucker rats. (Pubmed Central) - Nov 7, 2026
At the uterine level, LA reduced uterine diameter in obese rats but did not modify endometrial thickness. These findings indicate that LA produces markedly different reproductive responses according to the metabolic and reproductive context, improving several follicular and luteal histomorphometric indices in obese Zucker rats without a parallel restoration of uterine morphometry.
- | leuprolide acetate for depot suspension / Generic mfg.
Preclinical, Journal: Leuprolide acetate, a GnRH agonist, preserves cerebellar integrity and motor coordination in a rat model of hepatic encephalopathy. (Pubmed Central) - Nov 7, 2026
Treated animals exhibited reduced neuronal loss in the Purkinje and granular layers, decreased activation of caspase-8 and caspase-3, and increased expression of neurabin II and BDNF. Collectively, these findings indicate that LA has therapeutic potential to attenuate cerebellar neuronal damage and promote functional recovery during HE.
- | leuprolide acetate for depot suspension / Generic mfg.
Clinical, Retrospective data, Review, Journal: Gonadotropin-releasing hormone antagonists versus agonists for endometriosis: a systematic review and meta-analysis of randomized controlled trials. (Pubmed Central) - Nov 6, 2026
We performed a systematic review and meta-analysis of randomized controlled trials comparing GnRH-ant with leuprolide-based GnRH-a for the treatment of endometriosis, assessing symptom relief, pelvic signs, bone mineral density (BMD), quality of life, and hormonal outcomes...Long-term head-to-head trials are warranted. https://www.crd.york.ac.uk/PROSPERO/view/CRD420261289010, identifier CRD420261289010.
- Leukostasis in Setting of Acute Leukemia: A Rare Cause of Right Ventricular Failure & Group 5 Pulmonary Hypertension (Clinical Science Zone 1' Science and Technology Hall' South Hall' Leve; In-Person; Board no. 1136) - Nov 3, 2026 - Abstract #AHA2026AHA_12193;
This prompted initiation of emergent induction chemotherapy with leuprolide, daunorubicin, and cytarabine...Early recognition of RV failure and prompt initiation of supportive therapy, including diuresis and inhaled pulmonary vasodilation, were key strengths, along with treatment of the underlying leukemia. While rare, leukostasis?associated PH can be reversible with rapid cytoreduction, consistent with the partial improvement observed in this case, underscoring the need of coordinated multidisciplinary care.
- | Journal: A Systematic Review of Elagolix for the Management of Endometriosis-associated Pain. (Pubmed Central) - Nov 1, 2026
Elagolix represents an effective, patient centered therapeutic option for moderate to severe endometriosis associated pain, with a well characterized safety profile. Future research should address long term safety beyond 48 months, direct comparisons with first line hormonal therapies, and cost effectiveness in non US healthcare settings.
- leuprolide acetate for depot suspension / Generic mfg.
An Open-Label, Safety Extension Study for Subjects with Hormone-Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer Who Have Completed the OVarian Suppression Evaluating Subcutaneous LeuprolIde Acetate in Breast Cancer (OVELIA) Study (Exhibit Hall) - Oct 30, 2026 - Abstract #SABCS2026SABCS_370;
- | Journal, Tumor mutational burden, MSi-H Biomarker, PD(L)-1 Biomarker, IO biomarker, MSI-H: Durable biochemical and radiographic response during toripalimab treatment in MSI-high/TMB-high mCRPC: a case report. (Pubmed Central) - Oct 29, 2026
This single-case observation highlights the value of genomic profiling for mCRPC patients with relevant biomarkers. Readers should interpret these findings as hypothesis-generating and not proof of universal toripalimab activity.
- | leuprolide acetate for depot suspension / Generic mfg., cyproterone acetate / Generic mfg.
Enrollment change: PCNET: Comparison of Two Pharmacological Treatments of Pedophilia (clinicaltrials.gov) - Oct 28, 2026
P3, N=6, Terminated, Sponsor: Institut National de la Sant
Readers should interpret these findings as hypothesis-generating and not proof of universal toripalimab activity. N=48 --> 6
- progesterone / Generic mfg.
Cyclical Anaphylaxis Due to Progesterone Hypersensitivity in the Setting of Hereditary Alpha-Tryptasemia (Phoenix Convention Center ) - Oct 28, 2026 - Abstract #ACAAI2026ACAAI_1350;
Progesterone suppression such as elagolix can be both diagnostic and therapeutic. This case highlights the value of interdisciplinary collaboration in management of PH.
- | Truqap (capivasertib) / AstraZeneca
Trial completion date, Trial primary completion date: SNARE: A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss (clinicaltrials.gov) - Oct 26, 2026
P2, N=30, Recruiting, Sponsor: VA Office of Research and Development
This case highlights the value of interdisciplinary collaboration in management of PH. Trial completion date: Aug 2027 --> Jan 2029 | Trial primary completion date: May 2027 --> Oct 2028
- | leuprolide acetate for depot suspension / Generic mfg.
Enrollment change: Phase Ia Trial of HHK001 Compared With Enantone in Patients With Endometriosis (clinicaltrials.gov) - Oct 26, 2026
P1, N=20, Recruiting, Sponsor: Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.
Trial completion date: Aug 2027 --> Jan 2029 | Trial primary completion date: May 2027 --> Oct 2028 N=30 --> 20
- ||||| Kisqali (ribociclib) / Novartis
Enrollment closed: ADJUVANT WIDER: Phase IIIb Study of Ribociclib + ET in Early Breast Cancer (clinicaltrials.gov) - Oct 23, 2026
P3, N=1464, Active, not recruiting, Sponsor: Novartis Pharmaceuticals
N=30 --> 20 Recruiting --> Active, not recruiting
- | enzalutamide / Generic mfg., leuprolide acetate for depot suspension / Generic mfg., Cytovene (ganciclovir) / Roche
Journal: Gene Therapy for Metastatic Castration-Resistant Prostate Cancer Using the JC Polyomavirus (JCPyV) Virus-Like Particles as a Gene Delivery Vector. (Pubmed Central) - Oct 20, 2026
Recruiting --> Active, not recruiting These findings support that JCPyV-derived virus-like particles constitute a promising therapeutic approach for metastatic CRPC, enabling systemic delivery of suicide gene therapy with selective inhibition of tumor growth and translational relevance.
- | Erleada (apalutamide) / J&J, Firmagon (degarelix) / Astellas, Ferring, Orgovyx (relugolix) / Takeda, Sumitomo Pharma, Pfizer
Enrollment closed: VA STARPORT: Veterans Affairs Seamless Phase II/III Randomized Trial of STAndard Systemic theRapy With or Without PET-directed Local Therapy for Oligometastatic pRosTate Cancer (clinicaltrials.gov) - Oct 19, 2026
P2/3, N=378, Active, not recruiting, Sponsor: VA Office of Research and Development
These findings support that JCPyV-derived virus-like particles constitute a promising therapeutic approach for metastatic CRPC, enabling systemic delivery of suicide gene therapy with selective inhibition of tumor growth and translational relevance. Recruiting --> Active, not recruiting
- | leuprolide acetate for depot suspension / Generic mfg.
New trial: Public title: A Randomized, Open-label, Two-formulation, Single-dose, Parallel-group Bioequivalence Study of Leuprorelin Acetate Microspheres for Injection Administered Subcutaneously in Patients with Treatment-na (EUDRACT) - Oct 16, 2026
P=N/A, N=120, Recruiting, Sponsor: West China Hospital of Sichuan University; West China Hospital of Sichuan University
- | Kisqali (ribociclib) / Novartis
Enrollment open: A Multicenter Randomized Controlled Clinical Trial of Neoadjuvant Endocrine Therapy versus Chemotherapy in Patients with HR+/HER2- Early-Stage Breast Cancer (EUDRACT) - Oct 16, 2026
P4, N=148, Recruiting, Sponsor: Sun Yat-sen Memorial Hospital, Sun Yat-sen University; Sun Yat-sen Memorial Hospital, Sun Yat-sen University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | leuprolide acetate for depot suspension / Generic mfg.
Trial completion: Study on the role of probiotics in alleviating leuprolide-induced perimenopausal syndrome in assisted reproductive therapy (EUDRACT) - Oct 16, 2026
P=N/A, N=150, Completed, Sponsor: Reproductive Hospital Affiliated to Jiangxi University of Traditional Chinese Medicine; Reproductive Hospital Affiliated to Jiangxi University of Trad
Not yet recruiting --> Recruiting Not yet recruiting --> Completed
- || Herceptin (trastuzumab) / Roche, Perjeta (pertuzumab) / Roche
Trial completion date, Trial primary completion date: ADEPT: A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (clinicaltrials.gov) - Oct 6, 2026
P2, N=393, Active, not recruiting, Sponsor: Dana-Farber Cancer Institute
Not yet recruiting --> Completed Trial completion date: Sep 2030 --> Sep 2032 | Trial primary completion date: Mar 2026 --> Mar 2029
- leuprolide acetate for depot suspension / Generic mfg.
A Rare Case of Kidney Failure Due to Deeply Infiltrating Endometriosis and Nonsteroidal Anti-Inflammatory Drug Use (Exhibit Hall A, Convention Center) - Oct 2, 2026 - Abstract #KIDNEYWEEK2026KIDNEY_WEEK_4830;
She completed leuprolide therapy of endometriosis two months prior and had worsened abdominal pain afterwards, prompting NSAID use exceeding 3 g daily...Patients with CKD related to endometriosis have increased risks for deterioration of kidney function from both structural changes and NSAID use. Interdisciplinary management with a multimodal approach, preventive counseling and safe pain management are vital for staving off kidney failure and prolonging survival.
- enzalutamide / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
NELL-1-Associated Membranous Nephropathy in a Patient with Prostate (and Later Pancreatic) Cancer () - Oct 2, 2026 - Abstract #KIDNEYWEEK2026KIDNEY_WEEK_4296;
Further investigation need determine the mechanism linking antibody production and development of related MN. Our patient illustrates not only these principles, but also the potential for occult malignancy, present even as MN remission has been achieved.
- | leuprolide acetate for depot suspension / Generic mfg., bicalutamide / Generic mfg., flutamide / Generic mfg.
New P4 trial: ARCH: Autonomic and Renal Contributions to Hypertension With ADT (clinicaltrials.gov) - Sep 30, 2026
P4, N=50, Recruiting, Sponsor: Virginia Commonwealth University
- leuprolide acetate for depot suspension / Generic mfg.
Puberty Blockade Via Leuprolide Acetate Disrupts Bone Accrual in Adolescent Rats (Meeting Room 302) - Sep 20, 2026 - Abstract #ASBMR2026ASBMR_1893;
Ultimately, temporary suppression of puberty produced a transient, sex, and compartment-specific disruption of bone acquisition in rats. Whether longitudinal structural recovery fully restores peak bone mass, material quality, or strength remains a future direction.
- ||||| giredestrant (RG6171) / Roche
Enrollment closed, Trial primary completion date: CO44657: A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer) (clinicaltrials.gov) - Sep 14, 2026
P3, N=1050, Active, not recruiting, Sponsor: Hoffmann-La Roche
Whether longitudinal structural recovery fully restores peak bone mass, material quality, or strength remains a future direction. Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2027 --> Apr 2028
- | Enrollment open: ENHANCE: Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer (clinicaltrials.gov) - Sep 4, 2026
P3, N=1500, Recruiting, Sponsor: University College, London
Recruiting --> Active, not recruiting | Trial primary completion date: Feb 2027 --> Apr 2028 Not yet recruiting --> Recruiting
- | Firmagon (degarelix) / Astellas, Ferring, Orgovyx (relugolix) / Takeda, Sumitomo Pharma, Pfizer
New P2 trial: Short Course ADT for High Risk Low/Intermediate Risk ARTERA Prostate Cancer (clinicaltrials.gov) - Sep 3, 2026
P2, N=90, Recruiting, Sponsor: NYU Langone Health
- | New P2 trial: Neoadjuvant Endocrine Therapy Combined With Chemotherapy in ER-positive, HER2-negative Stage I-III Breast Cancer (clinicaltrials.gov) - Sep 3, 2026
P2, N=36, Not yet recruiting, Sponsor: The Second Hospital of Anhui Medical University
- | leuprolide acetate for depot suspension / Generic mfg.
Enrollment open: Phase Ia Trial of HHK001 Compared With Enantone in Patients With Endometriosis (clinicaltrials.gov) - Sep 2, 2026
P1, N=30, Recruiting, Sponsor: Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | Trial termination: ARCH: Contributions to Hypertension With Androgen Deprivation Therapy (clinicaltrials.gov) - Sep 2, 2026
P4, N=10, Terminated, Sponsor: University of Colorado, Denver
Not yet recruiting --> Recruiting Completed --> Terminated; Study completed
- Kisqali (ribociclib) / Novartis
Severe Delayed Ribociclib-Induced Liver Injury Despite Prolonged Drug Interruption (Exhibit Halls A - D (Level 3)) - Aug 29, 2026 - Abstract #ACG2026ACG_7072;
Although hepatotoxicity from CDK4/6 inhibitors is recognized, progression after prolonged drug interruption is uncommon and warrants vigilant monitoring. Figure: Trend of Liver Function Tests and Bilirubin during Hospitalization Figure: Laboratory values during the admission
- enzalutamide / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
More Than Meets the EUS: An Unusual Case of Mass-Forming Autoimmune Pancreatitis (Exhibit Halls A - D (Level 3)) - Aug 29, 2026 - Abstract #ACG2026ACG_843;
Figure: Trend of Liver Function Tests and Bilirubin during Hospitalization Figure: Laboratory values during the admission Interestingly, the patient
- | leuprolide acetate for depot suspension / Generic mfg.
New P1 trial: A Phase Ia Trial Comparing the Pharmacokinetics/Pharmacodynamics, Safety, and Preliminary Efficacy of HHK001 and Enantone in Patients With Endometriosis (clinicaltrials.gov) - Aug 28, 2026
P1, N=20, Not yet recruiting, Sponsor: The Third Xiangya Hospital of Central South University
- | Qibeian (iparomlimab/tuvonralimab) / Sound Biologics, Qilu Pharma
New P2 trial: QL1706 Plus Neoadjuvant Endocrine Therapy in HR-Positive/HER2-Negative Breast Cancer With a Poor Response to Neoadjuvant Chemotherapy (clinicaltrials.gov) - Aug 25, 2026
P2, N=40, Not yet recruiting, Sponsor: Hebei Medical University Fourth Hospital
- | Trial completion date: Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial (clinicaltrials.gov) - Aug 17, 2026
P3, N=2753, Active, not recruiting, Sponsor: NRG Oncology
Interestingly, the patient Trial completion date: Dec 2033 --> Dec 2038
- | Trial completion date: Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial (clinicaltrials.gov) - Aug 17, 2026
P3, N=2050, Active, not recruiting, Sponsor: NRG Oncology
Trial completion date: Dec 2033 --> Dec 2038 Trial completion date: Nov 2026 --> Nov 2031
- tamoxifen / Generic mfg.
Long-term Cardiovascular Outcomes With Aromatase Inhibitor Plus Ovarian Suppression Versus Tamoxifen In Premenopausal Breast Cancer: A Real-world Analysis [Poster no. 426] (ePoster Hub - Exhibit Hall 5-6 - PCC North; Monitor 28) - Aug 16, 2026 - Abstract #HFSA2026HFSA_888;
Among premenopausal breast cancer patients, AI plus ovarian suppression was not associated with increased short-term cardiovascular risk but was linked to higher long-term mortality and composite cardiovascular events compared with tamoxifen. The observed increase in stroke risk suggests a potential vascular effect of estrogen suppression, warranting further investigation and long-term cardiovascular surveillance in this population.
- ||||| leuprorelin acetate (DKF-MA102) / Dongkook Pharma
Trial completion, Trial completion date, Trial primary completion date: Efficacy and Safety of DKF-MA102 in Patients With Prostate Cancer (clinicaltrials.gov) - Aug 14, 2026
P3, N=161, Completed, Sponsor: Dongkook Pharmaceutical Co., Ltd.
The observed increase in stroke risk suggests a potential vascular effect of estrogen suppression, warranting further investigation and long-term cardiovascular surveillance in this population. Recruiting --> Completed | Trial completion date: May 2025 --> Mar 2026 | Trial primary completion date: May 2025 --> Jan 2026
- ||| enzalutamide / Generic mfg.
Enrollment closed: A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study (clinicaltrials.gov) - Aug 12, 2026
P2, N=900, Active, not recruiting, Sponsor: Astellas Pharma Global Development, Inc.
Recruiting --> Completed | Trial completion date: May 2025 --> Mar 2026 | Trial primary completion date: May 2025 --> Jan 2026 Recruiting --> Active, not recruiting
- | Opdivo (nivolumab) / Ono Pharmaceutical, BMS
Trial completion date: Nivolumab + Docetaxel + ADT in mHSPC Patients With DDRD or Inflamed Tumors (clinicaltrials.gov) - Aug 12, 2026
P2, N=47, Active, not recruiting, Sponsor: Xiao X. Wei, MD
Recruiting --> Active, not recruiting Trial completion date: Jun 2026 --> Oct 2026
- | leuprolide acetate for depot suspension / Generic mfg.
New P1 trial: Phase Ia Trial of HHK001 Compared With Enantone in Patients With Endometriosis (clinicaltrials.gov) - Aug 10, 2026
P1, N=30, Not yet recruiting, Sponsor: Zhuhai Huahaikang Pharmaceutical Technology Co., Ltd.
- ||||| Etcamah (camizestrant) / AstraZeneca
Enrollment closed: An Adjuvant Endocrine-based Therapy Study of Camizestrant (AZD9833) in ER+/HER2- Early Breast Cancer (CAMBRIA-2) (clinicaltrials.gov) - Aug 10, 2026
P3, N=5511, Active, not recruiting, Sponsor: AstraZeneca
Trial completion date: Jun 2026 --> Oct 2026 Recruiting --> Active, not recruiting
- | New P3 trial: ENHANCE: Evaluating Hormone Therapy to Achieve Optimal Doses in Metastatic Prostate Cancer (clinicaltrials.gov) - Aug 7, 2026
P3, N=1500, Not yet recruiting, Sponsor: University College, London
- Androgen Deprivation Therapy Is Associated With Reduced Risk of Androgen-Mediated Dermatologic Disease in Patients With Prostate Cancer (ePoster Area) - Aug 6, 2026 - Abstract #EADV2026EADV_2094;
These findings support the role of androgen signaling in sebaceous and follicular inflammatory pathways while suggesting no clear association with other inflammatory dermatoses such as psoriasis and lichen planus. ADT was not associated with increased risk of severe dermatologic drug reactions, xerosis, or hair loss.
- | Enrollment open: OPTIMA-YOUNG: Optimising Adjuvant Chemotherapy Prescription in Young Patients With Hormone-dependent Breast Cancer Using Genomic Tests (clinicaltrials.gov) - Jul 31, 2026
P3, N=3380, Recruiting, Sponsor: UNICANCER
ADT was not associated with increased risk of severe dermatologic drug reactions, xerosis, or hair loss. Not yet recruiting --> Recruiting
- leuprolide acetate for depot suspension / Generic mfg.
Enrollment open: A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty (clinicaltrials.gov) - Jul 29, 2026
P4, N=43, Recruiting, Sponsor: LG Chem
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- | leuprolide acetate for depot suspension / Generic mfg.
New P4 trial: A Study of Leuprorelin 1-Month (4-Week) Formulation in Children With Central Precocious Puberty (clinicaltrials.gov) - Jul 17, 2026
P4, N=43, Not yet recruiting, Sponsor: LG Chem
- Prolia (denosumab) / Amgen, Firmagon (degarelix) / Astellas, Ferring
Do diagnostic and therapeutic patterns influence the outcomes in patients with metastatic castration sensitive prostate cancer? Real-world data from 2 independent tertiary centers in Slovakia () - Jul 17, 2026 - Abstract #ESMO2026ESMO_5069;
Docetaxel and denosumab were more frequent in CO (87% vs 13% and 64% vs 36%, respectively)...No significant differences were observed in treatment outcomes (PSA?0.2: 63% vs 60%; PSA90: 98% vs 95%; progression: 34% vs 34%; mortality: 25% vs 25%; all p=NS). Similarly, Kaplan-Meier analysis showed no significant differences in PFS and OS (Log Rank test, p=NS).Conclusions Even though RWD confirmed differences in how oncologists and urologists manage mCSPC in Slovakia, both adhere to EAU/NCCN guidelines, resulting in comparable clinical outcomes such as PSA response, PFS, and OS.
- enzalutamide / Generic mfg., leuprolide acetate for depot suspension / Generic mfg.
Deep prostate-specific antigen (PSA) response by prior definitive treatment (tx) in patients (pts) with high-risk biochemically recurrent prostate cancer (hrBCR): EMBARK post hoc analysis (Poster Area - Hall 5) - Jul 17, 2026 - Abstract #ESMO2026ESMO_2712;
P3
Duration of PSA response (<0.2 ng/mL; <0.02 ng/mL) was generally longer or similar for enza + LA vs LA alone or enza mono across prior tx subgroups. Small sample sizes of the non-randomised prior tx subgroups should be considered when interpreting the results.
- leuprolide acetate for depot suspension / Generic mfg.
Puberty Blockade Via Leuprolide Acetate Disrupts Bone Accrual in Adolescent Rats (Discovery Hall - Exhibit Hall C & D) - Jul 11, 2026 - Abstract #ASBMR2026ASBMR_80;
Ultimately, temporary suppression of puberty produced a transient, sex, and compartment-specific disruption of bone acquisition in rats. Whether longitudinal structural recovery fully restores peak bone mass, material quality, or strength remains a future direction.
- | Lynparza (olaparib) / Merck (MSD), AstraZeneca
Enrollment closed, Trial primary completion date: NePtune: Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (clinicaltrials.gov) - Jul 10, 2026
P2, N=32, Active, not recruiting, Sponsor: Rana McKay, MD
Whether longitudinal structural recovery fully restores peak bone mass, material quality, or strength remains a future direction. Recruiting --> Active, not recruiting | Trial primary completion date: Mar 2026 --> Aug 2026